Drug Profile
Telitacicept - Yantai Rongchang Pharmaceutical
Alternative Names: RC-18; RCT-18; Tai’aiLatest Information Update: 22 Dec 2023
Price :
$50
*
At a glance
- Originator RC-Pharma
- Developer RemeGen
- Class Antirheumatics; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins; Urologics
- Mechanism of Action B cell activating factor inhibitors; Immunomodulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Systemic lupus erythematosus
- Preregistration Rheumatoid arthritis
- Phase III IgA nephropathy; Myasthenia gravis; Neuromyelitis optica
- Phase II Lupus nephritis; Multiple sclerosis; Sjogren's syndrome
Most Recent Events
- 06 Dec 2023 RemeGen terminates a phase II trial in IgA nephropathy (In adults, In the elderly) in USA (SC) due to decision that continuing with the study would not generate useful data (NCT04905212)
- 13 Nov 2023 RemeGen completes a phase-I trial in Systemic lupus erythematosus in China (NCT05247203)
- 10 Nov 2023 Adverse events and efficacy data from a phase III trial in Rheumatoid-arthritis presented at the American College of Rheumatology Convergence (ACR-2023)